Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

information fournie par Boursorama •31/07/2017 à 17:45

Strasbourg, France, July 31, 2017, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated in a Phase 1/2 clinical trial evaluating the combination of Pexa-Vec with Opdivo® (nivolumab) as a first-line treatment of advanced hepatocellular carcinoma (HCC), which accounts for approximately 75% of liver cancers. This open-label trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094).

The principal investigator of this multi-center trial is Prof Olivier Rosmorduc, MD, Head of Hepato-gastroenterology department at La Pitié-Salpêtrière Hospital in Paris (France).

More information on the trial is available on clinicaltrials.gov.
...